Lonidamine in primary malignant brain tumors. Preliminary report.
As part of a multicenter study on Lonidamine, this drug was studied in 16 patients with malignant gliomas. General and neurological examination, electroencephalography, electroneuromyography, and CT scan were repeated at regular intervals. The most common side effects were myalgia, nausea, and vomiting which usually subsided during treatment except in 4 patients. There was an indication of therapeutic activity in 4 out of 16 patients treated with Lonidamine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004562:Electrocardiography; D004576:Electromyography; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine